安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Ferring Pharmaceuticals | Cafepharma
Ferring Pharmaceuticals has been off to a strong start so far with Adstiladrin, which has yet to face similar hurdles as its gene therapy counterparts The bladder cancer treatment was recently ranked as the fourth best-selling gene therapy after its first full year on the market
- Ferring | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous board for Ferring Current openings in pharma and biotech
- Ferring’s microbiome and gene therapy firsts take the company beyond . . .
The privately held Swiss company scored two big FDA approvals at the tail end of 2022 There was the Clostridioides difficile (C diff) treatment Rebyota, which became the first FDA-approved fecal microbiota product A few weeks later came the nod for the vector-based gene therapy Adstiladrin, the first approved for bladder cancer
- Ferring shuts down U. S. -based research institute after more than 25 . . .
Ferring Pharmaceuticals is closing its San Diego-based research arm, resulting in layoffs that will affect 89 employees in California The company told employees about plans to shut down the Ferring Research Institute, according to a statement provided to Fierce Biotech No additional job losses are expected in the U S Source Fierce Biotech
- Pharma Biotech Companies | Cafepharma Message Boards | Pharma Sales . . .
Anonymous discussion boards for pharmaceutical and biotech companies
- Ferring, with manufacturing update, takes a step towards first gene . . .
Ferring Pharmaceuticals said Monday the Food and Drug Administration has cleared it to scale up manufacturing of its new gene therapy for bladder cancer
- Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical device sales, lab diagnostics sales
- Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma
Biopharma headlines today highlight funding declines, AI’s growing role in drug development and a mix of clinical wins and setbacks across obesity, oncology and neurodegenerative disease Novo Nordisk's strategic U S expansion with new board appointment Novo Nordisk board As Boehringer touts US launches, board chairman worries EU is 'falling further behind' Boehringer Ingelheim board
|
|
|